Shinya Sutani1, Toshio Ohashi2, Masanori Sakayori1, Tomoya Kaneda1, Shoji Yamashita3, Tetsuo Momma4, Takashi Hanada1, Yutaka Shiraishi1, Junichi Fukada1, Mototsugu Oya5, Naoyuki Shigematsu1. 1. Department of Radiology, Keio University School of Medicine, Japan. 2. Department of Radiology, Keio University School of Medicine, Japan; Department of Radiology, National Hospital Organization Saitama Hospital, Japan. Electronic address: ohashi@rad.med.keio.ac.jp. 3. Department of Radiology, National Hospital Organization Saitama Hospital, Japan. 4. Department of Urology, National Hospital Organization Saitama Hospital, Japan. 5. Department of Urology, Keio University School of Medicine, Japan.
Abstract
PURPOSE: To compare late genitourinary (GU) and gastrointestinal (GI) toxicity following different prostate cancer treatment modalities. MATERIALS AND METHODS: This study included 1084 consecutive prostate cancer patients treated with conventional radiotherapy, intensity-modulated radiotherapy (IMRT), permanent iodine-125 implantation (PI) alone, and PI combined with external beam radiotherapy (PI+EBRT). The effects of treatment- and patient-related factors on late grade ⩾ 2 (G2+) GU/GI toxicity risk were assessed. RESULTS: The median follow-up was 43 months (range, 12-97 months). Compared to the PI+EBRT, there was significantly less G2+ GU toxicity in the conventional radiotherapy (hazard ratio [HR] = 0.39; 95% CI, 0.20-0.77) and the IMRT (HR=0.45, 95% CI, 0.27-0.73). Compared to the PI+EBRT, there was significantly more G2+ GI toxicity in the IMRT (HR = 2.38; 95% CI, 1.16-4.87). In PI-related groups, prostate equivalent dose in 2 Gy fractions was a significant predictor of G2+ GU toxicity (p = 0.001), and the rectal volume receiving more than 100% of the prescribed dose was a significant predictor of G2+ GI toxicity (p = 0.001). CONCLUSION: The differences in the late G2+ GU/GI risk cannot be explained by the differences in treatment modalities themselves, but by the total radiation dose to the GU/GI tract, which had a causal role in the development of late G2+ GU/GI toxicity across all treatment modality groups.
PURPOSE: To compare late genitourinary (GU) and gastrointestinal (GI) toxicity following different prostate cancer treatment modalities. MATERIALS AND METHODS: This study included 1084 consecutive prostate cancerpatients treated with conventional radiotherapy, intensity-modulated radiotherapy (IMRT), permanent iodine-125 implantation (PI) alone, and PI combined with external beam radiotherapy (PI+EBRT). The effects of treatment- and patient-related factors on late grade ⩾ 2 (G2+) GU/GI toxicity risk were assessed. RESULTS: The median follow-up was 43 months (range, 12-97 months). Compared to the PI+EBRT, there was significantly less G2+ GU toxicity in the conventional radiotherapy (hazard ratio [HR] = 0.39; 95% CI, 0.20-0.77) and the IMRT (HR=0.45, 95% CI, 0.27-0.73). Compared to the PI+EBRT, there was significantly more G2+ GI toxicity in the IMRT (HR = 2.38; 95% CI, 1.16-4.87). In PI-related groups, prostate equivalent dose in 2 Gy fractions was a significant predictor of G2+ GU toxicity (p = 0.001), and the rectal volume receiving more than 100% of the prescribed dose was a significant predictor of G2+ GI toxicity (p = 0.001). CONCLUSION: The differences in the late G2+ GU/GI risk cannot be explained by the differences in treatment modalities themselves, but by the total radiation dose to the GU/GI tract, which had a causal role in the development of late G2+ GU/GI toxicity across all treatment modality groups.
Authors: Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert Journal: Radiat Oncol Date: 2016-10-31 Impact factor: 3.481
Authors: José Carlos Rodrigues Nascimento; Márcio Wilker Soares Campelo; Iuri Arruda Aragão; José Fernando Bastos de Moura; Lúcio Flávio Gonzaga Silva; Reinaldo Barreto Oriá Journal: Case Rep Med Date: 2017-06-21
Authors: Rowan V David; Arman A Kahokehr; Jason Lee; David I Watson; John Leung; Michael E O'Callaghan Journal: World J Urol Date: 2022-08-11 Impact factor: 3.661
Authors: Mahbubl Ahmed; Leila Dorling; Sarah Kerns; Laura Fachal; Rebecca Elliott; Matt Partliament; Barry S Rosenstein; Ana Vega; Antonio Gómez-Caamaño; Gill Barnett; David P Dearnaley; Emma Hall; Matt Sydes; Neil Burnet; Paul D P Pharoah; Ros Eeles; Catharine M L West Journal: Br J Cancer Date: 2016-04-12 Impact factor: 7.640